251 related articles for article (PubMed ID: 25760979)
1. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
Matikas A; Mavroudis D
Future Oncol; 2015; 11(6):997-1009. PubMed ID: 25760979
[TBL] [Abstract][Full Text] [Related]
2. Clinical deployment of antibodies for treatment of melanoma.
Curti BD; Urba WJ
Mol Immunol; 2015 Oct; 67(2 Pt A):18-27. PubMed ID: 25746916
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
4. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Therapy in Melanoma.
Callahan MK
Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of melanoma.
Kee D; McArthur G
Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
[TBL] [Abstract][Full Text] [Related]
7. Current and Emerging Perspectives on Immunotherapy for Melanoma.
Daud A
Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
An Q; Liu Z
BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
10. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of melanoma: present options and future promises.
Rotte A; Bhandaru M; Zhou Y; McElwee KJ
Cancer Metastasis Rev; 2015 Mar; 34(1):115-28. PubMed ID: 25589384
[TBL] [Abstract][Full Text] [Related]
13. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
15. Combination Immunotherapy Development in Melanoma.
Eggermont AMM; Crittenden M; Wargo J
Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.
Berraondo P; Ochoa MC; Rodriguez-Ruiz ME; Minute L; Lasarte JJ; Melero I
Cancer Res; 2016 May; 76(10):2863-7. PubMed ID: 27308833
[TBL] [Abstract][Full Text] [Related]
18. Cancer treatment: The killer within.
Ledford H
Nature; 2014 Apr; 508(7494):24-6. PubMed ID: 24695297
[No Abstract] [Full Text] [Related]
19. Immunotherapy for metastatic melanoma.
Zito CR; Kluger HM
J Cell Biochem; 2012 Mar; 113(3):725-34. PubMed ID: 22006439
[TBL] [Abstract][Full Text] [Related]
20. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach.
Agarwala SS; O'Day SJ
Cancer Treat Rev; 2011 Apr; 37(2):133-42. PubMed ID: 20638184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
